Visceral fat and metabolic syndrome: More than a simple association;Gordura visceral e síndrome metabólica: Mais que uma simples associação

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 2, 2006, Pages 230-238

  Ribeiro Filho, Fernando F ^a,b   Mariosa, Lydia S ^a   Ferreira, Sandra R G ^a   Zanella, Maria Teresa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cardiovascular risk; Insulin resistance; Metabolic syndrome; Visceral fat

Indexed keywords

CARDIOVASCULAR DISEASE; HUMAN; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; METABOLISM; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 33744454672     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000200009     Document Type: Review

References (86)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. DeFronzo RA, Ferraninni E. Insulin resistance - A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
3. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994;736(suppl):13-22.
4. Timar O, Sestier F, Levy E. Metabolic syndrome X: A review. Can J Cardiol 2000;16:779-89.
5. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002;25:829-34.
6. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-9.
7. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with metabolic syndrome. Diabetes Care 2001;24:683-9.
8. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-22.
9. Diabetes Atlas. Second edition. International Diabetes Federation; 2003.
10. Ford SE, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003;26:575-81.
11. Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K; Coronary Artery Risk Development in Young Adults study. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 2004;27: 2707-15.
12. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneve:World Health Organization; 1997.
13. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Rev 2000;21:697-738.
14. Matsunaga Y. Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 1997;13:3-13.
15. Ruderman N, Chisholm D, Pi-Sunyer, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699-13.
16. Sims EAH. Are there who are obese, but metabolically healthy? Metabolism 2001;50:1499-504.
17. Ferreira SR, Lerário DD, Gimeno SG, Sanudo A, Franco LJ; Japanese-Brazilian Diabetes Study Group. Prevalence and 7-year incidence of type II diabetes mellitus in a Japanese-Brazilian population: an alarming public health problem. Diabetologia 2002;45:1635-8.
18. Goodpaster BH, Krishnhaswami S, Harris TB, Katsiaras A, Kritchevsky SB, Simonsick EM, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005; 165:777-83.
19. Egger G. The case for using waist to hip ratio measurements in routine medical checks. Med J Aust 1992;156:280-5.
20. Fujimoto WY, Bergstrom RW, Bokyo EJ, Chen KW, Leonetti DL, Morris LN, et al. Visceral adiposity and incident coronary heart disease in Japanese-American men. Diabetes Care 1999;22:1808-12.
21. Lerário DD, Gimeno SG, Franco LJ, Iunes M, Ferreira SR. Weight excess and abdominal fat in the metabolic syndrome among Japanese-Brazilians. Rev Saúde Publica 2002;36:4-11.
22. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998;22:1145-58.
23. Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand 2005;183:13-30.
24. Harmelen VV, Reynisdottir S, Eriksson P, Thörne A, Hoffstedt J, Lönnqvist F, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998;47:913-7.
25. Vague J. The degree of masculine differentiation of obesity: a factor-determining predisposition to diabetes, atherosclerosis, gout, and uric acid calculus disease. Am J Clin Nutr 1956;4:20-34.
26. Després JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res 1998;6:8S-17S.
27. Lamarche B, Lemieux S, Dagenais GR, Depres JP. Visceral obesity and the risk of ischaemic heart disease: insights from the Quebec Cardiovascular Study. Growth Horm IGF Res 1998;8:1-8.
28. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000;23:465-71.
29. Ribeiro-Filho FF, Faria AN, Kohlmann NE, Zanella MT, Ferreira SR. Two-hour insulin determination improves the ability of abdominal fat measurement to identify risk for the metabolic syndrome. Diabetes Care 2003; 26:1725-30.
30. Faria AN, Ribeiro Filho FF, Gouveia Ferreira SR, Zanella MT. Impact of visceral fat on blood pressure and insulin sensitivity in hypertensive obese women. Obes Res 2002;10:1203-6.
31. Carneiro G, Faria AN, Ribeiro Filho FF, Guimarães A, Lerário D, Ferreira SR, et al. Influence of body fat distribution on the prevalence of arterial hypertension and other cardiovascular risk factors in obese patients. Rev Assoc Med Bras 2003;49:306-11.
32. Kobayashi H, Nakamura T, Miyaoka K, Nishida M, Funahashi T, Yamashita S, et al. Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ J 2001;65:193-9.
33. Frayn KN. Visceral fat and insulin resistance - causative or correlative? Br J Nutr 2000;83(suppl. 1):S71-7.
34. Lebovitz HE, Banerji MA. Pont: visceral fat is causally related to insulin resistance. Diabetes Care 2005;28:2322-5.
35. Miles JM, Jensen MD. Counterpoint: visceral adiposity is not causally related to insulin resistance. Diabetes Care 2005;28:2326-8.
36. Montague CT, O'Rahilly S. The perils of portliness. Causes and consequences of visceral adiposity. Diabetes 2000;49:883-8.
37. Mendoza-Nunes VM, Garcia-Sanchez A, Sanchez-Rodrigues M, Duarte REG, Yerena MEF. Overweight, waist circumference, age, gender, and insulin resistance as risk factors for hyperleptinemia. Obes Res 2002;10:253-9.
38. Kabir M, Catalano KJ, AnanthnarayanS, Kim SP, van Vitters GW, Dea MK, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005;288:E454-61.
39. Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes 1996;20:291-302.
40. Rosmond R, Björntorp P. The interactions between hypotalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men. Int J Obes 1998;22:1184-96.
41. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-3.
42. Stewart PM. Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome - 11beta-hydroxysteroid dehydrogenase type 1. Clin Med 2005;5:142-6.
43. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005;11:344-7.
44. Hall JE, Brands MW, Henegar JR, Shek EW. Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol 1998;25:58-64.
45. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14.
46. Hermsdorff HHM, Monteiro JBR. Gordura visceral, subcutânea ou intramuscular: onde está o problema? Arq Bras Endocrinol Metab 2004;48:803-11.
47. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr. AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
48. Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA, et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999;48:1332-5.
49. Borges RL, Ribeiro Filho FF, Carvalho KMB, Zanella MT. Redução do TNF-alfa com a perda de peso em pacientes hipertensos com obesidade central. Arq Bras Endocrinol Metab 2005;49/5(supl 2):S883.
50. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005;9:211-24.
51. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-8.
52. Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 2002;31:15-36.
53. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005;12:1931-45.
54. Anderson RA, Evans ML, Ellis GR, Graham J, Morris K, Jackson SK, et al. The relationships between postprandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 2001;154:475-83.
55. Bae JH, Bassenge E, Kim KB, Kim YN, Kim KS, Lee HJ, et al. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 2001;155:517-23.
56. Anderson RA, Evans ML, Ellis GR, Graham J, Morris K, Jackson SK, et al. The relationships between postprandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 2001;154:475-83.
57. Couillard C, Bergeron N, Prud'homme D, Tremblay A, Bergeron J, Bouchard C, et al. Gender difference in postprandial lipemia. Importance of visceral adipose tissue accumulation. Arterioscler Thromb Vasc Biol 1999;19:2448-55.
58. Blackburn P, Lamarche B, Couillard C, Pascot A, Bergeron N, Prud'homme D, et al. Postprandial hyperlipidemia: another correlate of the "hypertriglyceridemic waist" phenotype in men. Atherosclerosis 2003;171:327-36.
59. Gabriely I, Barzilai N. Surgical removal of visceral adipose tissue: effects on insulin action. Curr Diab Rep 2003;3:201-6.
60. Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002;26:193-9.
61. Rice T, Despres JP, Perusse L, Gagnon J, Leon AS, Skinner JS, et al. Segregation analysis of abdominal visceral fat: the HERITAGE Family Study. Obes Res 1997;5(5):417-24.
62. Nyholm B, Nielsen MF, Kristensen K, Nielsen S, Ostergard T, Pedersen SB, et al. Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients. Eur J Endocrinol. 2004;150:207-14.
63. Kelley DE, Thaete L, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 2000;278:E941-8.
64. Silva EA, Ribeiro-Filho FF, Zanella MT. Impact of visceral fat on insulin resistance, arterial hypertension and inflammatory markers. Hypertension 2005.
65. Kelley DE, Goodpaster BH, Storlien L. Muscle triglyceride and insulin resistance. Annu Rev Nutr 2002;22:325-46.
66. Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnodt B, et al. Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care 2004;27:2726-9.
67. Weber RV, Buckley MC, Fried SK, Kral JG. Subcutaneous lipectomy causes a metabolic syndrome in hamsters. Am J Physiol Regul Integr Comp Physiol 2000;279:936-43.
68. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549-57.
69. Rössner S, Bo WJ, Hiltbrandt E, Hinson W, Karstaedt N, Santago P, et al. Adipose tissue determinations in cadavers - a comparison between cross-sectional planimetry and computed tomography. Int J Obes 1990;14:893-02.
70. Yoshizumi T, Nakamura T, Yamane M, Islam AHW, Menju M, Yamasaki K, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999;211:283-6.
71. Kooy K, Seidell JC. Techniques for the measurements of visceral fat: a practical guide. Int J Obes 1993;17:187-96.
72. Williams MJ, Hunter GR, Kekes-Szabo T, Trueth MS, Snyder S, Berland L, et al. Intra-abdominal adipose tissue cut-points related to elevated cardiovascular risk in women. Int J Obes 1996;20:613-7.
73. Andreoli A, Melchiorri G, De Lorenzo A, Caruso I, Sinibaldi SP, Guerrisi M. Bioelectrical impedance measures in different position and vs dual-energy x-ray absorptiometry (DXA). J Sports Med Phys Fitness 2002;42:186-9.
74. Paradisi G, Smith L, Burtner C, Leaming R, Garvey WT, Hook G, et al. Dual energy x-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 1999;22:1310-7.
75. Lohman TG, Roche AF, Martorell R (eds). Anthropometric standardization reference manual. Illinois:Human Kinetics Books; 1998. p.177.
76. Seidell JC, Cigolini M, Charzeswka J, Ellsinger BM, Deslypere JP, Cruz A. Fat distribution in European men: a comparison of anthropometric measurements in relation to cardiovascular risk factors. Int J Obes 1992;16:17-22.
77. Molarius A, Seidell JC. Selection of anthropometric indicators for classification of abdominal fatness - a critical review. Int J Obes 1998; 22:719-27.
78. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486-97.
79. The International Diabetes Federation (IDF) worldwide definition of the metabolic syndrome. Available at: http://www.idf.org/webdata/docs/ IDF_Metasyndrome_ definition.pdf
80. Albu JB, Murphy L, Frager DH, Johnson JA, Pi-Sunyer FX. Visceral fat and race dependent health risks in obese nondiabetic premenopausal women. Diabetes 1997;46:456-62.
81. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of WHO consultation; 1999.
82. Armellini F, Zamboni M, Rigo L, Todesco T, Bergamo-Andreis IA, Procacci C, et al. The contribution of sonography to the measurement of intra-abdominal fat. J Clin Ultrasound 1990;18:563-7.
83. Armellini F, Zamboni M, Robbi R, Todesco T, Rigo L, Beragmo-Andreis IA, et al. Total and intra-abdominal fat measurements by ultrasound and computed tomography. Int J Obes 1993;17:209-14.
84. Leite CC, Wajchenberg BL, Radominski R, Matsuda D, Cerri GG, Halpern A. Intra-abdominal thickness by ultrasonography to predict risk factors for cardiovascular disease and its correlation with anthropometric measurements. Metabolism 2002;51:1034-40.
85. Ribeiro Filho FF, Faria AN, Kohlmann Jr. O, Ajzen S, Ribeiro AB, Zanella MT, et al. Ultrasonography for the evaluation of visceral fat and cardiovascular risk. Hypertension 2001;38:713-7.
86. Ribeiro Filho FF, Faria AN, Azjen S, Zanella MT, Ferreira SRG. Methods of estimation of visceral fat: advantages of ultrasonography. Obes Res 2003;11:1488-94.